Stockreport

Arch Therapeutics, Inc. $2.8 Million Registered Direct Offering

Arch Therapeutics, Inc.  (ARTH) 
NASDAQ:AMEX Investor Relations: ir.archtherapeutics.com
PDF FRAMINGHAM, Mass., May 13, 2019 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH)(“Arch” or the “Company”), a developer of novel liquid, gel and solid hemostat [Read more]